Bare Financial Services’s MoonLake Immunotherapeutics MLTX Stock Holding History

Bare Financial Services’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$351	Buy	+30	New	+$490	﹤0.01%	1857

Other funds holding MLTX

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Achmea Investment Management Zeist, Netherlands $12.6B AUM 25.68% 1-Year Est. Return

BankPlus Wealth Management Jackson, Mississippi $229M AUM 13.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Savant Capital Rockford, Illinois $35B AUM 15.18% 1-Year Est. Return

Bare Financial Services's MLTX Position: Q3 2026 in Review

Bare Financial Services opened a new position in MoonLake Immunotherapeutics (MLTX) in Q3 2026: 30 shares worth $351. The stake represents ﹤0.01% of the portfolio and ranks #1857 among its holdings.

41 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

Bare Financial Services held 30 shares of MoonLake Immunotherapeutics worth $351 as of Q3 2026.
MoonLake Immunotherapeutics was a new Bare Financial Services position in Q3 2026.
MoonLake Immunotherapeutics made up ﹤0.01% of Bare Financial Services's portfolio in Q3 2026, its #1857 holding.
41 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on Bare Financial Services's 13F filing for Q3 2026, filed 4 Nov 2026.